Table of Contents Table of Contents
Previous Page  574 / 1851 Next Page
Information
Show Menu
Previous Page 574 / 1851 Next Page
Page Background

Adjuvant Pembrolizumab after C-RT to st. III NSCLC

Durm ASCO 2017